March 2018
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
Following the publication of the Life Sciences Industrial Strategy, the Life Sciences Sector Deal and the Government response to the Accelerated Access Review, the seminar discussed the challenges and opportunities for improving access to medical treatments.
Key discussion points across the morning included:
- The policy context - implementing the strategy and the AAR, and next steps for medicines regulation after Brexit;
- Priorities for increased funding for research and development - with the Department of Health and Social Care and BEIS committing £160m to support the delivery of the AAR;
- The Accelerated Access Collaborative - its developing role and next steps for the pathway;
- Supporting innovation - funding, commissioning, dissemination, identifying transformative products and the future for horizon scanning;
- Data and evidence - key issues in using patient data to gauge the effectiveness of treatment and widen access;
- AHSNs - addressing infrastructural challenges, supporting the NHS and driving local routes to market;
- Clinical research - priorities for improving the UK science offer and encouraging early access; and
- Patients and the public - improving their involvement in the appraisal process.
